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If treatments for cognitive impairment are to be utilized suc-
cessfully, clinicians must be able to determine whether they 
are effective and which patients should receive them. In order 
to develop consensus on these issues, the International Society 
for CNS Clinical Trials and Methodology (ISCTM) held a 
meeting of experts on March 20, 2014, in Washington, DC. 
Consensus was reached on several important issues. Cognitive 
impairment and functional disability were viewed as equally 
important treatment targets. The group supported the notion 
that sufficient data are not available to exclude patients from 
available treatments on the basis of age, severity of cognitive 
impairment, severity of positive symptoms, or the potential to 
benefit functionally from treatment. The group reached con-
sensus that cognitive remediation is likely to provide substan-
tial benefits in combination with procognitive medications, 
although a substantial minority believed that medications 
can be administered without nonpharmacological therapy. 
There was little consensus on the best methods for assessing 
cognitive change in clinical practice. Some participants sup-
ported the view that performance-based measures are essen-
tial for measurement of cognitive change; others pointed to 
their cost and time requirements as evidence of impracticality. 
Interview-based measures of cognitive and functional change 
were viewed as more practical, but lacking validity without 
informant involvement or frequent contact from clinicians. 
The lack of consensus on assessment methods was viewed as 
attributable to differences in experience and education among 
key stakeholders and significant gaps in available empirical 
data. Research on the reliability, validity, sensitivity, and prac-
ticality of competing methods will facilitate consensus.
Key words: cognitive assessment/neuropsychology/treatment
Introduction
Cognitive impairment is a significant contributor to dis-
ability and poor functional outcomes in patients with 
schizophrenia.1,2 While antipsychotic medications are 
effective at reducing the psychotic symptoms of the illness, 
they have little impact on cognitive symptoms,3,4 and there 
are currently no approved treatments for cognitive impair-
ment associated with schizophrenia (CIAS). This signifi-
cant unmet need has been the focus of large government 
and industry initiatives in the United States5 and Europe,6 
which have stimulated and facilitated large drug develop-
ment programs for the treatment of CIAS.7,8 Further, sev-
eral behaviorally based cognitive remediation treatments 
have demonstrated modest success at improving CIAS,9 and 
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Food and Drug Administration (FDA) device clearance 
trials are ongoing (www.clinicaltrials.gov, NCT01422902). 
It is likely that by the end of this decade, a pharmacological 
or remediation-based treatment for CIAS will be approved 
by FDA and/or other regulatory agencies.
Prescribing physicians have become familiar with the 
evaluation of psychotic symptoms such as delusions, halluci-
nations, and agitation, which are the target of antipsychotic 
medications. These symptoms are often at the forefront of 
the clinical evaluation of the person with schizophrenia, par-
tially because they appear to call out for immediate interven-
tion in order to mitigate against ongoing patient suffering 
and harm to others. However, despite decades of research 
emphasizing the importance of cognition in predicting out-
come in schizophrenia and other disorders, evaluation of 
cognition is not a part of standard education or training, 
even in many advanced psychiatry residency programs and 
fellowships, and is not a component of a standard psychiatric 
diagnostic interview. If treatments for CIAS are to be utilized 
efficiently and successfully, it will be essential for physicians 
and other clinicians to be able to determine which patients 
should receive them, and whether such treatments are effec-
tive. The assessment of cognition in clinical practice needs 
development now so that appropriate tools and approaches 
will be available when treatments are approved for this indi-
cation. In order to generate discussion on these issues and 
to determine whether consensus is possible, the International 
Society for CNS Clinical Trials and Methodology (ISCTM) 
held a meeting to seek input from top experts in the field 
on March 20, 2014, in Washington, DC. While this group 
of experts was not without their own biases and potential 
conflicts of interest, it is a strong and effective tradition of 
ISCTM not to exclude those with conflicts of interest, but to 
require that they are transparent about their potential con-
flicts, and allow them to express their opinions in the open.
Aims of Meeting
The objective of this meeting was to determine the exist-
ing level of consensus on (1) methods for monitoring 
response to procognitive medications and interventions 
for patients with schizophrenia; (2) the necessary tools 
and training to conduct this assessment in the clinic set-
ting; and (3) approaches to prescribing procognitive med-
ications and interventions in the clinic.
Methods
Survey
Survey questions were developed by the project Steering 
Committee and sent to 46 experts in schizophrenia, cognition, 
clinical trials, community psychiatry, and drug development. 
They were selected on the basis of their field of expertise, 
to ensure adequate representation from all areas of interest, 
and their availability. The group included academic psychol-
ogists and psychiatrists, community psychiatrists, physicians, 
pharmacologists and psychologists from industry, and a 
consumer representative. Thirty-four (73%) respondents 
completed the survey. A small number of questions were not 
clearly understood based on comments from the experts and 
data from these questions were disregarded. Most questions 
revealed significant disagreement or divergence of opinions 
and were the focus of discussion at this meeting. The data 
collected from the survey helped to shape the questions that 
would be addressed at the consensus meeting.
Discussion
A group of 23 experts in cognition, schizophrenia, com-
munity psychiatry, and drug development were selected 
from the pool of 46 experts who completed the survey 
and invited to participate as panelists (herein referred 
to as “panelists”) at the consensus meeting. They were 
selected on the basis of their perceived contributions to 
this area of research and their field of expertise to ensure 
adequate representation from all areas of interest. The 
panel included 8 academic psychologists, 7 academic psy-
chiatrists, 5 community psychiatrists, 4 physicians and 
a pharmacologist from industry, and a consumer rep-
resentative. Fourteen panel members were prescribing 
physicians. In addition, the consensus meeting was open 
to audience participants (herein referred to as “partici-
pants”) who were interested in the discussion. The size of 
the audience participants was capped at 70.
The meeting began with a brief description, including 
pros and cons, of several cognitive assessment methods to 
ground panelists in their understanding of these tools. The 
central theme under consideration was to address the pre-
ferred method, if any, for monitoring response to treatment 
assuming that a medication or intervention is available for 
treating cognitive impairment in schizophrenia. Factors 
considered were complexity of administration, sensitivity 
and reliability, time, costs, reimbursement, and training. 
The remainder of the meeting consisted of very brief pre-
sentations on opposing sides of an issue or question, fol-
lowed by extensive discussion by all panelists. At the end 
of the meeting, all of the questions that were discussed and 
debated during the conference were posed to the panelists 
for a final vote, and their responses were recorded with an 
audience response system. The audience participants were 
asked to record their responses on paper forms, which were 
collected following the meeting. This report is a product of 
the discussions and final voting at the meeting.
Review of Assessment Methods for Cognition and 
Functional Outcomes
In order to establish whether a patient is responding to 
treatment for CIAS, there are a variety of options available. 
One decision is whether to focus on cognitive performance, 
which is the most immediate treatment target, or to focus 
on functional outcomes, which have greater clinical mean-
ing and relevance to a patient’s everyday life, but may be 
more challenging to observe change. For the purposes of 
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this discussion, the following categories were used: compre-
hensive cognitive performance assessments, brief cognitive 
performance assessments, interview-based measures of cog-
nition, performance-based measures of functional capacity, 
and interview-based assessment of real-world functioning. 
These assessment methods are summarized in table 1.
Comprehensive Cognitive Performance Assessment. 
Cognition, or the ability to think and process infor-
mation, has several components or domains.10,11 The 
Neurocognition Subcommittee of the Measurement 
and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) Project chose 7 of them for 
the MATRICS Consensus Cognition Battery (MCCB) to 
be used in clinical trials assessing the efficacy of cognition-
enhancing medications.10 Considerations for selection of 
domains were severity of impairment, relation to func-
tional outcome, and feasibility for clinical trials.
Patients with schizophrenia vary greatly in their pro-
file and severity of their cognitive impairment. Only by 
comprehensive assessment of various domains of cogni-
tive functioning can response to the relevant aspects of 
cognitive impairment treatment be properly monitored. 
Further, superficial assessment of a cognitive domain is 
not sufficient; to be useful in clinical practice, cognitive 
tests require enough items to generate test-retest reliabil-
ity that will enable sensitivity to change.12–14 Short tests 
or test batteries often have reduced reliability. A reliable 
change index calculates the amount of change that will be 
consistent with a predetermined percentage of change in 
a distribution. Usually, the chosen cutoff  is 90%, mean-
ing only 10% of the population will demonstrate that 
amount of change by chance. As an example, recent data 
collected on the MATRICS battery and its domains sug-
gest that an approximately 10 point change on the MCCB 
composite score is needed to be 90% confident that the 
change is due to treatment effects.15 This is consistent with 
earlier studies of other batteries as well as measures of 
functional capacity.16–20 For clinicians who wish to relax 
the threshold for what is considered treatment response 
or worsening, it is possible to use a reliable change index 
with a 80% CI, which will reduce the MCCB composite 
score threshold to about 8 points.
The primary drawbacks of comprehensive assessment 
however are time and personnel required. The MCCB 
requires about 75 min to administer to the patient, with 
scoring and interpretation requiring at least another 
30 min for the tester. Other comprehensive test batteries 
may require as much or more time. Computerized test 
batteries such as the CogState battery or the Cambridge 
Neuropsychological Test Automated Battery (CANTAB) 
assess most or all of the MATRICS domains. These com-
puterized batteries may require less time for scoring but 
may have other implementation challenges, such as miss-
ing data.21 Many clinical practices have neither the time 
nor staff  members with the proper training to complete 
cognitive assessment. This issue is reduced with comput-
erized tests; however, adequate tester training and cre-
dentials, as well as supervision of test administration, are 
essential. Many test batteries are copyrighted and have 
acquisition costs that reduce enthusiasm for this method 
of assessment.
Brief Cognitive Performance Assessment. There are 
test batteries available with various numbers of assess-
ments. The Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) has 10 tests covering 
5 domains and requires 45 min, and the Brief  Assessment 
of Cognition in Schizophrenia (BACS) has 6 tests and 
requires 35 min. Various combinations of existing tests 
have also been studied, including the Brief  Cognitive 
Assessment,22 the Brief  Cognitive Assessment Tool for 
Schizophrenia,23 each of which trim the number of tests 
to 3, and then most recently the Brief  Neurocognitive 
Assessment (BNA) which has only 2 tests.24 The ideal 
length of a test battery for evaluating general cognitive 
changes in a clinical setting is not established. The amount 
of variance in overall test performance that is accounted 
for by each successive test suggests diminishing returns 
after about 4 tests,25 but some argue that smaller batteries 
are equally sensitive.23,24
The drawbacks to using brief  assessments are that they 
reduce the number of domains that can be tested and can 
reduce the test-retest reliability of assessment and jeopar-
dize the ability of the assessment to detect treatment benefit 
or decline. Thus, treatments with significant benefits to 
patients can look like failures, and deleterious effects on 
cognition will appear benign. The costs of brief  batteries 
are less, but staff  members who have proper credentials 
and supervision remain essential. Companies that sell the 
tests require supervision by a psychologist because subtle 
changes in test administration and scoring can have a tre-
mendous effect on a patient’s scores.
Performance-Based Measures of Functional Capacity. A 
recent development in research on the determinants of 
disability in schizophrenia has been performance-based 
measures of functional capacity.26 These assessments have 
found that impairments predict failures to achieve mile-
stones in vocational, residential, and social domains27,28 
in schizophrenia and bipolar disorder populations.29,30 
Whether everyday functioning is defined either by mile-
stone achievement31 or by ratings generated by high-con-
tact informants,29 impairments on measures of functional 
capacity have typically been found to be more proximal 
to everyday functional deficits than cognitive impair-
ments.20,29 Further, the correlation between performance 
on functional capacity measures and cognitive tests has 
been remarkably consistent and substantial, typically 
r  =  .60 or greater.32,33 Measures of functional capacity 
may be more strongly correlated with real-world func-
tioning than cognitive measures.29
22
R. S. E. Keefe et al
Table 1. Cognitive Assessment Methods
Category Examples Advantages Disadvantages References
Comprehensive 
Cognitive 
Performance 
Assessments
•   MATRICS  
Consensus Cognition 
Battery (MCCB)
•   CogState
•   Cambridge 
Neuropsychological  
Test Automated  
Battery (CANTAB)
•   Numerous tests  
available in all 7 
MATRICS domains
•   Addresses all 7 cognitive domains 
recognized by MATRICS
•   Sufficient items to generate test-retest 
reliability that will enable sensitivity to 
change
•   Associated with change index to  
calculate the amount of change that  
will define improvement or worsening
•   Time requirements: 
75 min to administer; 
30 min to score and 
interpret for MCCB  
(less time for CogState 
and CANTAB)
•   Missing data can create 
scoring challenges
•   Require adequate tester 
training and credentials,  
as well as supervision of 
test administration
•   Many are copyrighted 
and have acquisition costs
Nuechterlein 
et al,10 Pietrzak 
et al,34 and  
Barnett et al35
Brief  Cognitive 
Performance 
Assessment
•   Repeatable Battery 
for the Assessment of 
Neuropsychological  
Status (RBANS)
•   Brief  Assessment 
of Cognition in  
Schizophrenia (BACS)
•   Brief  Cognitive 
Assessment
•   Brief  Cognitive 
Assessment Tool for 
Schizophrenia
•   Brief  Neurocognitive 
Assessment (BNA)
•   Addresses most domains but  
administered in shorter period of time  
than comprehensive batteries
•   Evidence suggests that shorter tests  
are equally sensitive
•   Lower costs
•   Short tests or test  
batteries often have 
reduced reliability
•   Reduced number of 
domains tested
•   Testers require training 
and supervision
Green et al,12 
Buchanan et al,13 
Umbricht et al,14 
Velligan et al,22 
Hurford et al,23 and 
Fervaha et al24
Performance-
based Measures 
of Functional 
Capacity
•   UCSD Performance- 
based Skills 
Assessment  
(UPSA)—several 
variants
•   Test of Adaptive 
Behavior in 
Schizophrenia  
(TABS)
•   Independent Living 
Scales (ILS)
•   Able to predict failures to achieve 
milestones in vocational, residential, and 
social domains in schizophrenia and  
bipolar disorder populations
•   Functional capacity is more proximal  
to everyday functional deficits than 
cognitive impairments
•   Correlation between performance on 
functional capacity measures and  
cognitive tests has been remarkably 
consistent and substantial
•   Measures of functional capacity may be 
more strongly correlated with real-world 
functioning than cognitive measures
•   Easily tolerated and practical to utilize
•   Demonstrated high levels of test-retest 
reliability, minimal practice effects, and 
minimal missing data in large-scale  
clinical trials
•   Relationship of these 
functional capacity 
measures to cognitive 
change may be indirect
•   Most are in a paper and 
pencil format
•   Comprised of several 
functional tasks that are 
not required consistently 
across different cultures
•   Most lack alternate  
forms which make them 
prone to high practice 
effects
•   Prone to ceiling effects in 
high functioning patients, 
limiting sensitivity
Green et al,12 
Mausbach et al,27 
Mausbach et al,28 
Bowie et al,29  
Leifker et al,36  
Green et al,32  
Keefe et al,33,  
Velligan et al,37  
and Bowie et al38
Interview-based 
Measures of 
Cognition
•   Cognitive  
Assessment Interview 
(CAI)
•   Measure of Insight  
into Cognition
•   Schizophrenia  
Cognition Rating  
Scale (SCoRS)
•   Brief  administration time, requiring 
(~15 min per interview)
•   Good relationship to real-world 
functioning
•   Good test-retest reliability
•   High correlation with some  
performance-based measures  
of cognition
•   Weak relationship to 
objective cognitive and 
functional measures
•   Validity and correlations 
with performance- 
based measures depends 
upon the availability of 
informant
•   Some training is required
Green et al,12  
Green et al,32 
Saperstein et al,39 
Keefe et al,40  
and Ventura et al,41
Interview-based 
Assessments 
of Real-world 
Functioning
Specific Levels of 
Functioning (SLOF)
•   Assesses social functioning, vocational  
or nonvocational productive functioning, 
and residential independence and self-care
•   Functional scales acceptably correlated 
with performance-based measures
•   Requires input of 
informants such as 
friends or relatives or 
those with a caregiver 
relationship
•   Changes are likely to take 
far longer to detect
Durand et al,42  
Sabbag et al,46 and 
Patterson et al,42,44 
Buchanan et al45
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Functional capacity measures are easily tolerated and 
practical to utilize.12,32,37 They have demonstrated high levels 
of test-retest reliability, minimal practice effects, and mini-
mal missing data in large-scale clinical trials.33 However, 
despite these multiple strong features, there are some limi-
tations to the current set of functional capacity measures. 
The relationship of these measures to cognitive change 
may be indirect.29 Most of these measures are delivered in a 
paper and pencil format, which is not practical for remote 
delivery or for simultaneous assessment of multiple cases. 
Further, these measures are comprised of several functional 
tasks that are not required consistently across different cul-
tures and do not have alternate forms.37 Because many of 
these measures were developed to assess the severity of 
disability, patients who are high functioning may perform 
near perfectly at baseline and thus cannot demonstrate 
improvement.
Interview-Based Measures of Cognition. Many clinicians 
who might wish to evaluate the effect of treatment on cog-
nitive impairment in their patients with schizophrenia do 
not have the required expertise or resources to conduct 
the meaningful performance-based assessments discussed 
above. Furthermore, the interpretation of the clinical rel-
evance of changes in performance-based measures is not 
immediately accessible to non-experts, including clini-
cians, consumers, and family members, and may require 
different approaches or supplemental assessments with 
greater face validity. Clinicians may prefer an assessment 
that they can utilize to assess cognitive change in their 
patients in situations where performance-based cognitive 
tests are not practically available. Interview-based assess-
ments have the potential to meet these requirements.
The strengths of interview-based assessments of cogni-
tion such as the Measure of Insight into Cognition,39 the 
Schizophrenia Cognition Rating Scale (SCoRS),40 or the 
Cognitive Assessment Interview (CAI)41 are brief admin-
istration time, requiring about 15 min per interview,33,41,42 
relation to real-world functioning,25,42,46 good test-retest 
reliability, and correlations with at least some performance-
based measures of cognition.12,25,33,40,42,46 However, several 
challenges remain. Many studies have found no relation 
of interview-based measures to objective cognitive and 
functional measures.39 Due to the difficulties that patients 
with schizophrenia have reporting accurate information 
regarding cognition and everyday functioning,43,46 the 
validity of the interview-based measures and their correla-
tions with performance-based measures of cognition may 
depend upon the availability of an informant. Because 
some patients with schizophrenia may not have contacts 
who know them well and are available to be interviewed,44,47 
requirements for informant information may reduce the 
practicality of interview-based methods of assessment. 
Finally, while training demands are less than comprehen-
sive performance-based cognitive assessment, some train-
ing is required.
Interview-Based Assessment of Real-World Functioning. 
The domains of community functioning that are nor-
mally assessed are social functioning, vocational or 
non-vocational productive functioning, and residential 
independence and self-care. These aspects of function-
ing are assessed by self-report, through the involvement 
of relatives, friends and caregivers who provide informa-
tion as informants, and clinicians. This information can 
also be obtained through reliable records and accurate 
archival materials. Important milestones for real-world 
functioning include obtaining, maintaining, or advanc-
ing employment; achieving residential independence; and 
marriage. Sub-threshold activities include taking steps 
toward these milestones such as seeking a job, receiving 
training that may enhance the likelihood of employment, 
or attending group social activities.
There are several different functional status rating scales 
that are used to examine these aspects of everyday func-
tioning. A comparative head to head study19 suggested that 
the Specific Levels of Functioning48 was the best scale for 
identification of aspects of everyday functioning when the 
reference point was performance-based measures of cogni-
tion and everyday functional skills. Follow-up analyses of 
the database44 revealed that most of the 6 functional scales 
examined yielded ratings that were acceptably correlated 
with performance-based measures. An important caveat, 
however, is that ratings that were solely dependent on the 
self-report of patients or the reports of friends or relatives 
with a non-caregiver relationship to the patient yielded 
ratings with minimal validity. These data, consistent with 
interview-based measures aimed at cognition, suggest 
that the assessment of everyday outcomes requires an 
approach that involves more detail than just asking ques-
tions to the patient. At the same time, clinicians, who have 
frequent contact with a patient, including case managers 
and psychiatrists, generate everyday functioning ratings 
that are quite convergent with other assessments based on 
performance and ratings of cognitive functioning. One of 
the main drawbacks of the use of real-world functioning 
assessments to measure treatment response is that changes 
in these outcomes, unlike changes in cognition and func-
tional capacity, are likely to take far longer than a short 
treatment trial. This is the main reason that the FDA does 
not require changes in functional outcomes for approval 
of cognitive-enhancing medications in schizophrenia.45
Results
Discussion and Voting of the Panelists on 
Relevant Issues
In order to address which of these methods are best used 
in the clinical assessment of cognitive treatment response, 
several issues were debated. This was followed by a vote by 
the 23 panelists. The viewpoints and voting of the panel-
ists will be summarized here and described in detail in an 
online supplementary appendix. A 7-point Likert scale was 
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used on all questions discussed. The anchors were 1 = com-
pletely agree and 7 = completely disagree. As data are pre-
sented, agreement on a particular point or question included 
responses 1–3; while disagreement included responses 5–7. 
Response 4 was considered neutral. Audience participant 
responses are noted only when substantially different from 
the panelists. A summary of voting at the meeting on out-
come measure preferences is displayed in table 2.
Cognition vs Functioning. This discussion addressed the 
issue of whether improvements in cognition or function-
ing defined a response to treatment. (Functioning refers to 
a patient’s ability to execute activities in the community.)
The arguments made in favor of cognition noted that 
the treatment would putatively be approved for improve-
ments in cognition and that the clinical evaluation should 
be consistent with the labeling language. Determinations 
about whether the drug is effective should be made in 
a way that is consistent with the indication, which is 
cognitive impairment. Because many sources influence 
functioning, an evaluation of the drug should be cir-
cumscribed to cognitive effects. Because cognitive benefit 
may not necessarily lead to functional changes, it will be 
important for the prescriber to know if  the drug is having 
an effect on cognition and to be able to make medication 
decisions due to lack of efficacy in an individual patient.
The arguments made in favor of a focus on function-
ing are that because the ultimate goal of treatment is to 
improve patients’ lives, clinical evaluation must empha-
size improvements made in their ability to perform in the 
community. Baseline assessment of a patient’s goals and 
reasons for wanting to receive treatment can facilitate an 
ongoing consideration of whether a patient is making 
progress toward meeting the goals of treatment.
Consensus There was a lack of consensus by the experts 
on the question of whether cognition and functioning are of 
primary importance in the evaluation of efficacy for a cog-
nitive-enhancing treatment. Both were seen as important.
Formal Cognitive Assessment: Strengths, Weaknesses, 
and Alternatives. This debate centered on whether for-
mal assessments of treatment response are warranted or 
necessary or whether informal assessments of treatment 
response are sufficient. The arguments in favor of formal 
Table 2. Panelist (N = 23) Voting Summary on Cognition Assessment Questions
Issue or Question Mean Votea
Level of 
Agreement 
(Vote 1–3) Recommendation
Is efficacy defined as improvement in cognition? 2.7 83% No consensus
Is efficacy defined as improvement in functioning? 2.5 67%
The impracticality of formal cognition testing outweighs their 
validity for monitoring in clinical practice
4.4 39% No consensus
Patient interviews are adequate to assess treatment response 5.5 30% High-contact clinicians can 
assess treatment response; 
patient interviews alone are not 
adequate
The perspective of a reliable informant is vital to the assessment of 
treatment response
3.5 48%
High-contact clinicians are able to reliably assess functional outcomes 2.7 83%
Very brief  (<5 min) assessments of cognition represents the 
maximum that a community psychiatrist can devote
Rank ordered (see Figure 1) No consensus
Brief  assessments (<10 min) of cognition will adequately assess 
cognition in the clinical setting
Self-administered tests of cognition represent the optimal balance 
of time, effort, training, and feedback
Performance-based measures of functional capacity, including 
computerized simulations, provide more information than measures 
of cognition and take about the same amount of time and effort
An interview-based assessment of everyday functioning or cognitive 
functioning provides an assessment of the ultimate goal of treatment 
and a confirmation of the clinical relevance of improvement
Breadth (more domains) vs depth (more trials per domain) is 
the most important aspect of cognitive performance testing for 
evaluation treatment response in a clinical setting
47.5% support breadth No consensus
30.4% support depth
aVoting on a 1–7 Likert scale, with 1 = full agreement and 7 = no agreement.
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performance-based assessment of cognitive change were 
that these measures are objective, reliable, and less suscep-
tible to biases such as placebo and halo effects than sub-
jective or self-report measures. Standardized criteria for 
cognitive improvement and sensitivity to change could be 
established in order to facilitate the use of these measures. 
Further, while clinicians may not currently utilize them, 
if  they become convinced that these tools are an impor-
tant component of their clinical practice, they may learn 
how to implement and interpret them and thus change the 
way they practice. In-office testing is feasible and is often 
completed in many areas of medicine where laboratory 
procedures such as blood tests, physiological measures, 
and imaging are a part of the standard understanding of 
a patient’s condition and response to treatment.
Web-based tools such as “test my brain” may be use-
ful. These web-based methods establish large databases 
from volunteer users that can serve as population norms. 
Recent work comparing web-based databases with labo-
ratory data suggests that there are surprisingly few dif-
ferences between them.49 Further, patients appreciate 
receiving this source of feedback, and it can be highly 
cost effective, with very little burden on clinicians. If  web-
based assessment proves to be valid and can be included 
as part of the assessment conducted in the late stages of 
drug development, it would reassure payers. If  this test-
ing is reimbursed, it is far more likely to be used in clinical 
practice. Among the drawbacks of this recently developed 
approach, however, are that the reliability and validity of 
these types of assessments have not been established in 
schizophrenia patient populations, and the role of clini-
cians and the potential burden on them may be similar to 
that of traditional cognitive performance testing.
The arguments against formal performance-based 
assessment of cognitive change in clinical practice were 
that (1) required cognitive testing is inconsistent with cur-
rent standards of care in psychiatry; (2) it would be difficult 
or impossible to provide prescribers with meaningful guide-
lines for how to interpret changes in cognitive tests; and (3) 
time would be better spent evaluating client perspectives on 
cognitive functioning and measuring functional outcomes.
Formal evaluation with performance-based tests is 
not required nor routinely conducted in the evaluation 
of response to medications targeting other psychiatric 
domains such as depression, anxiety, psychotic symptoms, 
and negative symptoms. Even for diseases where cogni-
tive impairment is the accepted treatment target such as 
Alzheimer’s disease or Attention Deficit Hyperactivity 
Disorder, formal performance-based evaluation is rarely 
completed and would not have an impact on treatment 
decisions. Mandated cognitive testing would likely increase 
the cost of treating cognitive disability in persons with psy-
chiatric disorders. Such testing would impose an additional 
burden on prescribers, which could lead to fewer clients 
receiving these medications than would otherwise benefit, 
as has long been the case of clozapine in the United States. 
Further, as current psychological assessment guidelines 
require the assessments to be performed by qualified psy-
chologists, the many clinical sites that lack a psychologist 
could be forced into a situation where the requirements 
force noncompliance with professional standards.
Consensus Regarding the question of whether formal 
assessments of treatment response are warranted or neces-
sary or whether informal assessments of treatment response 
are sufficient, consensus was not reached among the panelists.
Interview-Based Measures: Strengths, Weaknesses, and 
Alternatives. This section was divided into 3 perspec-
tives. The first perspective was that patient interviews are 
sufficient to assess response in situations where cognition 
must be subjectively assessed. In order to achieve this 
goal, however, clinicians must have historical and ongoing 
knowledge of the patient and understand that schizophre-
nia is a multidimensional disorder. The extent of experi-
ence a clinician has with similar patients will enable him or 
her to compare among patients. Moving forward, systems 
of care must provide ongoing education for clinicians 
regarding multidimensional assessment. Finally, training 
of mental health professionals and prescribers must be 
revamped to emphasize multidimensional assessment.
The second perspective was that because patient reports 
about cognition are often unreliable and uncorrelated with 
cognitive performance testing, the perspective of a reliable 
informant such as a friend or family member is vital to the 
assessment of cognitive treatment response. In contrast to 
patient reports, correlations between cognitive performance 
and informant reports tend to be between r = .3 and .4, which 
are medium effect sizes and suggest that informants can 
report on cognitive impairment in the patients they know. 
Most importantly, analyses of clinical trials data testing the 
efficacy of a cognitive-enhancing compound suggest that the 
addition of informants in the use of interview-based cognitive 
assessments may enhance the sensitivity of the measure to 
treatment response.50,51 This area remains in a nascent stage, 
and new data continue to emerge on the capacity of training 
and assessment conditions to affect the sensitivity of patient- 
vs informant-interviews and the relative value of various 
informants such as parents, siblings, friends, and caseworkers.
The third perspective was that clinicians with a high fre-
quency of contact with the patient such as therapists or 
case managers are able to assess functional outcomes reli-
ably. Many patients have difficulty reliably reporting on even 
simple concrete behavior such as whether they are currently 
employed and mood symptoms account for greater vari-
ability in scores than cognitive impairment. However, the 
scores that high-contact clinicians derive from the same func-
tional outcomes in their patients are strongly correlated with 
patients’ severity of cognitive impairment. One of the clear 
challenges with this approach is that some systems of care do 
not enable any clinicians to have a high frequency of contact.
Consensus There was strong consensus that clinicians 
can assess response if  they have frequent contact with 
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the patient and that patient interviews alone are not suf-
ficient. The role of informants is important but depends 
upon the frequency of contact with the patient and the 
nature of the relationship with the patient.
Further Considerations of Assessment Methods and 
Time Constraints
Several presentations and discussion focused on the 
strengths and weaknesses of specific methods of assess-
ment based upon the resources and time that are available 
to clinicians. A summary of these discussions is presented 
in the supplementary appendix.
Review of Prioritization Voting. Based on the discus-
sion of assessment methods throughout the meeting, 
panelists were asked to rank order each of the following 
methods for their value in assessing cognitive treatment 
response in a clinical setting: comprehensive cognitive 
performance assessment (1–2 h of testing); brief  cogni-
tive performance assessments (15–30 min); briefer cog-
nitive performance assessments (<10 min); very brief  
(<5 min) cognitive performance; self-administered tests 
of cognition; performance-based measures of functional 
capacity; and interview-based assessment of everyday 
functioning or cognitive functioning. Scoring methods 
are described in the supplementary appendix.
The results (see figure 1) were noteworthy for having 4 
methods with similar scores at the top of the rankings and 
3 with similar scores at the bottom of the rankings. Very 
brief, self-administered, and comprehensive cognitive 
assessments were not supported by the group in general, 
although there was considerable spread in scores and some 
panelists did rank one or more of these methods. Overall, 
however, the other 4 methods, brief (15–30 min) cognitive 
assessments, performance-based measures of functional 
capacity, briefer (5–10 min) cognitive assessments, and 
interview-based measures of cognition and functioning, 
were more highly ranked.
Consensus Consensus on prioritization of methods was 
not reached. As reflected by the discussion, there was 
ongoing disagreement among the panelists regarding the 
best methods for assessing cognitive treatment response. 
Community and clinical psychiatrists emphasized the 
need for brief  assessments, while academicians and psy-
chologists emphasized the poor psychometric charac-
teristics of these methods, and favored more rigorous 
methods requiring greater patient and staff  time.
Patient Selection
As with any treatment for a new indication, treatment 
guidelines and answers to key treatment questions should 
arise from leaders in the field in a consensus document. 
This is certainly applicable in the case of CIAS. Despite 
high anticipation for medications to address this huge 
unmet need, many clinicians may have questions about 
ideal patient types to be treated. For example, is everyone 
with schizophrenia a candidate for treatment? If  not, how 
are treatment initiation decisions made? The discussions 
focused on the questions of whether patient selection 
should be based on:
 • age and duration of illness
 • baseline level of cognition
 • baseline level of everyday functioning
 • severity of positive symptoms
These are topics for which no studies have been done and 
few data exist. There are several key stakeholders with 
interests in answers to these questions, including payers. 
In the absence of product-specific data to guide answers 
to these questions, the panel debated these points in gen-
eral terms. A  summary of panelist voting is shown in 
table 3.
Fig. 1. Weighted evaluation of assessment methods.
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Patient Selection With Respect to Age/Duration of 
Illness. This debate centered on whether age and/or 
duration of illness should be a determinant in selecting 
patients for initiation of treatment. For sake of discus-
sion, a “younger” patient is someone with the illness for 
10  years duration or less. Two contrasting viewpoints 
were presented: (1) younger patients or those earlier in 
the course of their illness should be considered for treat-
ment vs those with longstanding illness and (2) treatment 
should be initiated regardless of age or duration of illness.
Arguments for suggesting that younger patients may be 
more amenable to treatment were (1) altered neurobiology in 
the aging brain affords reduced likelihood or opportunity for 
neuroplasticity and thus recovery of function in older peo-
ple52; (2) younger people are more proximal to job, school, 
or other type of community activity, so less retraining would 
be involved; and (3) younger people are consequently more 
likely to demonstrate improvements in real-world activities 
like returning to work. On the other hand, as long as the 
medication in question does not demonstrate preferential 
effects in younger vs older people, a person’s age should not 
be a factor in patient selection. A key supporting argument 
is the lack of data to infer that younger patients will be more 
functionally responsive, which has not been shown in cog-
nitive remediation studies. A second point is that depriving 
patients with longstanding disease of a potentially effective 
medication may be viewed as unethical.
Consensus There was clear consensus that age and 
duration of illness should not be a consideration in 
patient selection for procognitive treatments. However, if  
resources are limited, the panelists viewed younger and 
less chronic patients as a priority.
Patient Selection With Respect to Level of Cognitive 
Impairment. The discussion on patient selection with 
respect to baseline level of impairment was focused on 
whether there should be predilection for selecting patients 
with a higher level of cognition or functioning. The assump-
tion is the treatment effect of the intervention does not have 
a preferential effect based on level of cognition. The prin-
cipal arguments in support of such a position are that the 
less impaired patients (1) simply need a little boost to get 
them “over the hump” to better community functioning 
and (2) can more easily demonstrate functional improve-
ments than persons with greater impairment. Further to 
the second point, the potential functional improvement in 
a patient who requires a substantial amount of support, 
unless the effect of the intervention is truly large, is unlikely 
to result in a change in dependency status. There were 
also arguments in support of preferentially selecting for 
Table 3. Panelist Voting (N = 23) Summary on Cognition Treatment-Related Questions
Issue or Question
Mean 
Votea
Level of 
Agreement 
(Vote 1–3) Recommendation
Treatment should be initiated regardless of age or duration of illness 1.9 91% Age or duration of illness should not be a 
consideration in patient selection
If age and chronicity are considered, younger, less chronic patients 
should be treated in favor of older, more chronic patients
2.2 78% N/A
Treatment should be initiated independent of a patient’s baseline 
level of cognitive impairment
2.5 78% Level of severity of cognitive impairment should 
not be a consideration in patient selection
If level of severity is important in patient selection, less impaired 
patients should be selected in favor of more severely impaired patients
3.7 31% N/A
Treatment of cognitive impairment in clinical practice should be 
initiated independent of a patient’s level of everyday functioning
3.3 61% Treatment should be initiated in patients independent 
of their opportunity to improve functionally
If  baseline level of functioning is considered, treatment should 
focus on patients with lower levels of everyday functioning
4.6 13% N/A
Medication treatment of cognitive impairment should be restricted 
to patients whose positive symptoms are stable and low/moderate
5.2 22% Treatment can be initiated with or without the 
presence of low-moderate or relatively unstable 
positive symptoms
Nonpharmacological treatments will provide substantive benefits 
to drug treatments
2.3 87% Cognitive remediation is likely to enhance drug 
treatment benefit, but should not be required for 
drug treatment to be initiated
Nonpharmacological treatments are an essential component of 
cognitive enhancement
3.4 56%
Drugs labeled for adjunctive use with cognitive remediation would 
discourage use of these medications
2.2 82%
aVoting on a 1–7 Likert scale, with 1 = full agreement and 7 = no agreement.
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treatment patients with greater levels of impairment: (1) 
ethics—depriving an effective medication from a severely 
ill segment of the population is unethical and (2) cognitive 
and functional improvements in persons with low levels of 
cognition may actually be easier to perceive than in those 
with higher cognitive ability. An analogy to this is the use 
of clozapine in treatment-resistant patients where improve-
ment is easy to detect. Furthermore, functional milestones 
are applicable to all patients, regardless of their cognitive 
ability. Milestones of a person with low functional ability 
are every bit as meaningful as those in patients with high 
functional ability.
Consensus Which patients receive treatment should not 
depend upon their baseline level of cognitive impairment.
Patient Selection Based on Opportunity to Functionally 
Improve. The panel discussed the selection of patients 
for treatment based on their opportunity to improve func-
tionally, meaning they are in a work, living, training/edu-
cation, or social situation that afforded opportunities to 
implement skills to improve their functioning and/or are 
receiving psychosocial rehabilitation targeting these com-
monly espoused recovery goals. The contrasting perspec-
tives were (1) patient selection should favor those who have 
an opportunity to improve functionally because functional 
improvement is the primary goal of treatment and psycho-
social rehabilitation programs can be a potent moderator 
of cognitive benefits from cognitive enhancement and (2) 
most patients can be treated regardless of their opportunity 
to improve functionally because noticeable improvement in 
one aspect of cognition defines efficacy. The principal argu-
ment in support of the first perspective was that opportu-
nities or situations to improve functionally, such as a job, 
school, or even management of daily living skills, enable 
patients to exercise their cognition. Those patients who 
have no opportunities to make functional changes or are 
not engaged in psychosocial rehabilitation programs will 
not benefit sufficiently to make treatment valuable,9,53 and 
lack of functional opportunities may limit the extent to 
which cognitive change improves everyday functioning.29,54
On the other hand, it can be argued that most patients 
should be treated regardless of opportunity to improve 
functionally because of (1) the lack of precision in iden-
tifying potential responders; (2) a wide variation among 
patients may exist in terms of what defines a functional 
response, with many patients facing functional challenges 
that are immutable; and (3) withholding an approved 
treatment from someone who lacks an opportunity to 
functionally improve may be viewed as unethical. All 
patients who have a need to improve functionally warrant 
a therapeutic trial with a treatment.
Consensus Treatment should be initiated in patients 
independent of their opportunity to improve functionally.
Patient Selection Based on Stability and Extent of Positive 
Symptoms. Clinical studies evaluating the procognitive 
effects of potential medications in the treatment of cog-
nitive impairment identify only subjects who meet cer-
tain stability criteria for enrollment. Predominant among 
these selection criteria are that positive symptoms are no 
worse than mild-moderate and that they are relatively 
stable. Additional criteria are stable doses of background 
antipsychotic medications, minimal extrapyramidal 
symptoms, and no symptoms of depression. The primary 
purpose of these criteria is to ensure that changes observed 
in cognition are attributed to the intervention (study drug) 
and not changes in other facets of their disease. With 
these stability criteria, the applicability of efficacy data to 
the entire population of patients, particularly those whose 
symptoms are less stable, could be questioned. Therefore, 
the panelists debated whether procognitive treatments 
should be limited to relatively stable patients with low 
levels of positive symptoms. Further debate was held on 
the fate of treatments during periods of positive symptom 
acute exacerbation. The purpose of this discussion was 
to formulate recommendations to the field on prescribing 
medications to patients whose symptom levels were out-
side the scope of those persons with schizophrenia who 
had participated in cognitive enhancement clinical trials.
Arguments made in support of limiting treatments in 
patients whose symptoms are stable and low were mainly 
limited to initiation of treatment, not maintenance. If  
there were no data to support the benefits of treatments 
in patients with fluctuating symptoms, the cost and safety 
risks, depending in the profile of the medication in ques-
tion, may not justify the prescription. There was no sup-
port among the panelists for discontinuing treatment if  
a patient’s symptoms worsened or became unstable after 
starting treatment. The points made in support of treat-
ing a broad group of patients irrespective of the degree 
of positive symptoms were (1) little correlation between 
positive symptoms and cognition; (2) the likely targets for 
cognitive-enhancing drugs are independent of psychosis; 
(3) effective cognition treatments will likely require con-
tinuous dosing, rather than stopping and starting with 
symptom fluctuations; and (4) successful treatments for 
cognitive impairment may enable some patients to par-
ticipate in programs that otherwise would not be possible.
Consensus Treatment can be initiated in a patient popu-
lation that is likely to respond to treatment, with or with-
out the presence of low-moderate or relatively unstable 
positive symptoms. Furthermore, procognitive medica-
tions need not be discontinued during periods of acute 
exacerbation of psychosis.
Use of Procognitive Medications With Nonpharmacological 
Treatments. Because there are no approved pharmaco-
logical methods of treating CIAS, no data exist on the 
combination of cognitive remediation or behavioral 
therapy with pharmacological treatments. Of course, 
final decisions about implementing cognitive remedia-
tion strategies during clinical trials and during clinical 
29
ISCTM Report on Clinical Assessment of Cognitive Treatment
practice will be determined by several important factors, 
including the mechanism of action of the treatment and 
the perceived need for experience-based learning to be 
used alongside novel pharmacology. The discussion and 
voting at the meeting were completed not to preempt 
these important issues but to understand the current 
thinking on these topics from experts in this area of work 
as well as from industry leaders who may be considering 
the inclusion of cognitive remediation treatments in their 
future clinical trials. Therefore, the panel addressed the 
necessity and uncertainty of combining nonpharmaco-
logical and pharmacological treatments on patient out-
comes. Issues related to the strength of the dependence 
of pharmacologic treatment on the presence of behav-
ioral treatment were discussed at 3 different levels: (1) 
will nonpharmacological treatments provide substantive 
benefits to drug treatments; (2) will nonpharmacological 
treatments be an essential component to drug treatment; 
and (3) if  nonpharmacological treatments are a neces-
sary adjunct to drug treatment, what will be the impact 
on drug prescribing?
Cognitive remediation has a high potential to increase 
the efficiency of drug treatments.55,56 Meta-analyses indi-
cate the general treatment effect size associated with cog-
nitive remediation therapy is approximately 0.36–0.45.9,53 
Pharmacologic treatment may have the potential to 
address lower level cognitive functions in a more efficient 
manner than cognitive remediation. The combination 
would enable cognitive remediation to focus on higher 
level cognitive processes, such as problem solving, that 
may not be as amenable to pharmacotherapy. Cognitive 
remediation can then promote generalization of cogni-
tive benefit by teaching how to use the pharmacologi-
cally enhanced skills to perform the multidimensional 
cognitive tasks.
It can be argued that nonpharmacological treatments 
are an essential component of cognitive enhancement. 
Some believe, although supportive data do not exist, that 
administering a pharmacologic treatment without retrain-
ing or education is futile. The rationale for this hypothesis is 
that medications are likely to improve a patient’s cognitive 
abilities but daily activities may not include tasks that foster 
these abilities. A close analogue is d-cycloserine in the treat-
ment of anxiety disorders, where data suggest that training 
is necessary for behavioral gains to be realized.57 The coun-
ter argument to this perspective is that because the improve-
ments resulting from behavioral cognitive remediation and 
pharmacologic treatment may be overlapping, utilizing both 
treatments at the same time is redundant and unnecessary.
The impact on prescribing procognitive drugs was dis-
cussed under the assumption that studies will show pro-
cognitive medications are effective only in combination 
with cognitive remediation, and this would be reflected in 
the label. Much of this impact was dependent on (1) prac-
tice setting/prescriber and (2) patient access to cognitive 
remediation. In an acute inpatient facility, the short stay 
is more conducive to cognitive assessment and psycho-
education about cognitive health than starting a course 
of cognitive remediation which on average runs for 32 
sessions. Making cognitive remediation available on an 
acute unit is not likely to improve short-term outcome, 
reduce patient costs, or increase institutional revenue. 
Therefore, in acute care settings, it would be burdensome 
and of no benefit to require cognitive remediation in 
addition to prescribing a medication. However, cognitive 
remediation could be prescribed for initiation during out-
patient treatment. In a long-term inpatient facility, treat-
ment focuses on symptomatic stabilization and preparing 
the patient for community reentry. Given their longer 
length of stays, cognitive remediation plus medication 
in this situation may be cost-effective. However, in many 
regions of the United States and throughout the world, 
cognitive remediation in these facilities is largely unavail-
able. Therefore, access to cognitive remediation would 
persist as a rate-limiting constraint to prescribing. The 
treatment focus in day treatment and partial hospitaliza-
tion programs is on symptom stabilization and optimiz-
ing community function. Initiating cognitive remediation 
in these facilities is certainly within the scope of practice; 
however, as in long-term inpatient facilities, the unavail-
ability of cognitive remediation at this time would be a 
rate-limiting factor. In outpatient sites, cognitive remedi-
ation is more widely available. However, transportation, 
cost, and noncompliance pose huge constraints on its 
effectiveness.
Consensus The group was clear that cognitive remediation 
is likely to facilitate and potentially enhance a drug treat-
ment benefit. However, about half of the panelists believed 
that some form of nonpharmacological treatment is needed 
in combination with medication treatments; without behav-
ioral treatment, improved cognition cannot be attained. 
About one-third of the panelists believed that medications 
were acceptable to administer without nonpharmacologi-
cal therapy. Cognitive remediation should not be required 
for drug treatment to be initiated. The group recommended 
that drug companies and other developers of procognitive 
medications study the additive benefits of cognitive reme-
diation and other nonpharmacological treatments in the 
development of procognitive medications and that data be 
published or included in product labeling.
Conclusions
The panelists, who came from very diverse backgrounds 
in terms of career and educational focus, reached strong 
consensus on only a few topics. The discussions and vot-
ing were striking not only for the breadth of opinion but 
also for their resistance to significant change following 
discussion. Some of the challenge of reaching consensus 
was attributable to the absence of clear data to allow the 
creation of informed opinion, particularly with regard 
to the absence of an approved treatment for cognitive 
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impairment in schizophrenia. The output from this meet-
ing suggests that additional research on these issues is 
necessary, and the results reported here may provide a 
roadmap for future work. In addition, dissemination of 
this work will be essential for the various stakeholders to 
come to a significant alignment on the various methods 
for assessing cognitive change in clinical settings.
Group voting from the panelists and audience partici-
pants suggested agreement that both cognition and func-
tioning are equally important in the evaluation of efficacy 
for a cognitive-enhancing treatment. This result has impor-
tant implications for the development of clinical trials meth-
odology and educational programs for clinicians. First, 
it will be important to know the cognitive and functional 
changes associated with any new treatments under evalu-
ation, and thus the development of new treatments should 
include functional and cognitive outcome measures. In 
addition, efforts to educate clinicians on the evaluation of 
treatment response should include both types of outcomes.
No consensus was reached on whether the impracti-
cality of formal assessments of cognition outweighs their 
validity for monitoring treatment in clinical practice. 
Some panelists and participants, particularly those in 
clinical practice with substantial time and resource con-
cerns, favored brief  assessments and a focus on interview-
based techniques. Other panelists, particularly researchers 
and psychologists with concerns about the psychometric 
characteristics and validity of the outcome measures, 
favored longer assessments with standardized methods of 
evaluation. This divergence was considerable and reflects 
existing differences among mental health professionals in 
their approach to clinical evaluation. It is unreasonable 
to expect that these differences will be narrowed consid-
erably. However, it will continue to be valuable for those 
representing these different perspectives to inform one 
another of relevant empirical data as they emerge.
There was strong consensus that clinicians can assess 
response if they have frequent contact with the patient. 
However, there was also strong consensus that patient inter-
views alone are not sufficient. There was consensus that the 
gaps in information provided by patients themselves can 
be filled by people who observe patients in their everyday 
lives. However, there was also clear consensus that the con-
tribution of an informant depends upon the frequency of 
contact that an informant has with the patient.
Regarding the central question of which specific assess-
ment methods are most favorable for clinical evaluation 
of treatment response, there was no clear consensus. Brief  
performance-based cognitive assessments, interview-
based assessments, and performance-based measures of 
functional capacity were viewed as slightly more favor-
able than comprehensive test batteries, very brief  assess-
ment, or self-administered computerized cognitive tests.
Although the group did not reach consensus on the 
practicality of formal testing, a number of members 
expressed enthusiasm for cognitive assessments that could 
be administered in a clinic office with minimal training by 
office staff. There was agreement that it was feasible to 
develop cognitive tests that would be administered on a 
tablet or a similar device. Results could be delivered to the 
clinician with minimal delay. It is important to note that 
participants were not aware of a validated assessment 
that is currently available to provide this service.
There was considerable agreement among the panelists 
and participants on what factors should be considered 
in selecting patients for treatment. The group attained 
consensus that patient selection should not depend upon 
age or chronicity, baseline level of cognitive or func-
tional impairment, or the severity of positive symptoms. 
However, the groups conceded that as treatments are 
developed, empirical data may become available that help 
target specific patient populations for specific treatments.
In summary, broad consensus was reached on most 
topics related to patient selection and treatment, and these 
conclusions can be usefully applied when treatments for 
cognitive impairment become available for people with 
schizophrenia. However, there was only moderate con-
sensus on the majority of the questions addressing treat-
ment goals and methods for monitoring cognitive deficit 
treatment response in clinical practice. The disagreement 
among participants was largely explained by the lack of 
solid data on these topics. The discordance observed at 
this conference around optimal monitoring of cognition 
in the clinical setting may be addressed by further devel-
opment and validation of instruments to measure cogni-
tion and functioning, with the busy practicing clinician 
in mind as the end user. There appears to be a dearth of 
brief and psychometrically valid tools that can be easily 
used by nonpsychologist clinicians to measure cognition 
in their offices. How can large databases and web-based 
data collection facilitate this progress? Is it possible to 
develop tools that can be used without specialized train-
ing? Finally, it will be important to include key stakehold-
ers—patients, families, payers—into the discussion so that 
these new tools can include their input about the compo-
nents of cognition that are most worrisome to them.
It is important for the field to develop these tools now 
so that when treatments for cognitive impairment become 
available, the tools to monitor patient progress will be 
ready. The criteria for the usefulness of cognitive outcome 
measures in clinical trials and clinical practice have con-
siderable overlap.58 As described above, these measures 
need to have strong test-retest reliability, validity, correla-
tions with functional outcomes, minimal practice effects, 
sensitivity to diagnostic differences, and sensitivity to 
treatment effects. They should also be practical for testers 
and tolerable for patients. It is essential that any new tools 
for measuring cognition in clinical practice meet these 
criteria. They will also need to demonstrate the flexibil-
ity that is found in traditional cognitive tests. While sig-
nificant promise to improve the efficiency of testing and 
therefore allow greater numbers of patients to be tested, 
31
ISCTM Report on Clinical Assessment of Cognitive Treatment
these measures will need to improve upon previously high 
missing data rates.21,25 As described by Bauer et  al59 in 
their joint position paper of the American Academy of 
Clinical Neuropsychology and the National Academy of 
Neuropsychology, performance claims for electronic out-
come measures will need to meet FDA Center for Drug 
Evaluation Research device regulations, with encryption 
for “store and forward” procedures, and proper privacy 
and identity verification mechanisms, preferably with bio-
metric login systems. These devices should be configured 
so that they do not discriminate against patients based 
upon age, race, education, or socioeconomic status, which 
can be complicated when utilizing technologies that may 
be very familiar to some individuals while others have not 
used them. Finally, the lure of the device should not be 
the governing factor in outcome choice. The determina-
tion of the value of a measure should be its contribution 
to clinical decision making, not whether it makes the cli-
nician feel more technologically sophisticated.
Finally, considerable progress in recent years has 
empirically linked cognition to community outcomes, 
but more work is needed to move this important area of 
research into the practicing clinician’s office. The authors 
also recommend that psychiatry training programs pro-
vide greater attention to cognitive treatments and meth-
ods for assessment so that emerging clinical psychiatrists 
are aware of how to address cognitive impairment in their 
patients with schizophrenia.
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Supplementary material is available at http://schizophre-
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